Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Incorporating I-O Therapies in the Treatment Landscape for Patients with Pathologically High-risk Urothelial Carcinoma Originating in the Bladder
Thursday, January 18, 2024 | 3 p.m. EST
Historically, the standard of care for muscle invasive urothelial carcinoma (MIUC) was radical surgery with cisplatin-based chemotherapy in eligible populations; however, more than 50% of patients still have a metastatic progression following radical surgery. This non-CME webinar will focus on the opportunity to highlight the need for additional treatments in patients with UC post-radical resection. A urology expert will provide scientific rationale to support how patients with UC at a high-risk of recurrence after radical resection may benefit from adjuvant immunotherapy treatment. In support of improving patient care, the urology expert will characterize the importance of communication across the multidisciplinary team, the central role of the urologist and how they can help to manage IO-therapies.
Gautam Jayram, MD
Dr. Jayram is a urologist and Director of the Advanced Therapeutics Center at Urology Associates, PC, in Nashville, Tennessee. He attended Vanderbilt University School of Medicine and completed his urology residency at the University of Chicago Hospitals. He then spent two years in Baltimore, Maryland, where he completed a fellowship at Johns Hopkins’ Brady Urological Institute and served as a clinical instructor.
Dr. Jayram has a busy urologic oncology practice in Nashville and performs a high volume of prostate, bladder, and kidney cancer procedures yearly. At the Advanced Therapeutics Center, he directs one of the busiest urologic cancer clinical trials programs in the country. He has served in several advisory roles and sits on multiple trial steering committees. He currently is very involved in improving oncology clinical pathways for community urology and sits on the Education Committee for the Large Urology Group Practice Association (LUGPA).